Drug intelligence / Profile preview

SLX-9031

Development stage: Preclinical
Lead developer: Biolexis Therapeutics
Modality: Small Molecules

Overview

SLX-9031 is a novel, selective small molecule inhibitor of Transglutaminase 2 (TGM2) being developed by Biolexis Therapeutics for the treatment of glioblastoma. TGM2 is a calcium-dependent enzyme that cross-links extracellular matrix (ECM) proteins, contributing to tumor microenvironment stability, cell proliferation, and resistance to therapy. SLX-9031 was identified via fragment-based lead optimization from the MolecuLern library and has shown an IC50 of 1.5 uM in cell-free assays, along with promising activity in U138 and U87 glioblastoma cell lines. The compound is currently undergoing preclinical evaluation, including ADME and in vivo pharmacokinetic studies, to assess its potential as a targeted therapy for glioblastoma.

Targets

TGM2 (Tissue Transglutaminase 2)

Beyond the preview

Go deeper on SLX-9031.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SLX-9031.

Explore the full profile